Filter Results
:
(175)
Show Results For
-
All HBS Web
(175)
- People (1)
- News (53)
- Research (81)
- Events (3)
- Multimedia (9)
- Faculty Publications (48)
Show Results For
-
All HBS Web
(175)
- People (1)
- News (53)
- Research (81)
- Events (3)
- Multimedia (9)
- Faculty Publications (48)
←
Page 9 of
175
Results
- 19 May 2009
- First Look
First Look: May 19, 2009
the significance levels are lower. Cases & Course MaterialsAdnexus Therapeutics, Inc.: Considering the Exit Harvard Business School Case 609-015 Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology...
View Details
Keywords:
Martha Lagace
- 28 Apr 2009
- First Look
First Look: April 28, 2009
Industry Location and International Regulatory Variation Author:Arthur A. Daemmrich Publication:Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, 271-290. Berlin, Germany: Max Planck...
View Details
Keywords:
Martha Lagace
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
drugs (chemically-synthesized, “small-molecule” drugs) face price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already approved original...
View Details
Keywords:
Sean Silverthorne
- 01 Feb 1997
- News
Shaping the Future of Business: Entrepreneurial Evolution at HBS
a thriving organization of significant scale. Gordon M. Binder (MBA '62) played a key role in just such a transition at Amgen, which now ranks as the largest biotechnology firm in the world. A California-based firm that discovers, develops, manufactures, and markets...
View Details
- 08 Jun 2010
- First Look
First Look: June 8
uncertainty of commercial partners' interest in the therapeutic approach, and the constrained donor-based fundraising environment. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/610074-PDF-ENG Data.gov Karim R. Lakhani, Robert...
View Details
Keywords:
Martha Lagace
- 01 Dec 2013
- News
Curing Health Care
products. Stock predicts that the development pace for personalized therapeutics and preventive diagnostics will pick up speed, thanks to the beneficial add-on effects derived from identifying more and more biomarkers for particular...
View Details
- Web
Print View - Course Catalog
new custom designed materials could be grown rather than manufactured. Companies like Verve Therapeutics announced the first human trials of a single shot cure for all heart attacks through a one-time change in a single gene. In most of...
View Details
- ←
- 9